Best of ASCO 2023, Minneapolis

Bloomington, MN US
August 12, 2023 to August 13, 2023

This CME-accredited oncology conference, Best of ASCO 2023, Minneapolis, is designed to improve the care of cancer patients by educating clinicians involved in cancer care.  

Expert faculty will provide a comprehensive overview of practice-changing abstracts presented at the 2023 ASCO® Annual Meeting (ASCO2023) in June 2023. The program includes in-depth discussion and analysis of the latest scientific findings and practice-changing advances in the field. Expert faculty will place abstract findings from ASCO2023 into clinical contexts and discuss how the results may change the current standard of care.

Target Audience

  • Medical oncologists
  • Radiation oncologists
  • Surgical oncologists
  • Oncology residents/fellows
  • Oncology NPs/PAs
  • Oncology pharmacists
  • Oncology nurses

HOTEL RESERVATIONS

A limited number of rooms have been booked at the Hyatt Regency- Bloomington Minneapolis for participants of this meeting at a discounted room rate of $149/night for the standard rooms. Individual Reservations must be made no later than July 21, 2023. Please get in touch with reservations directly at (800) 233-1234.

Learning Objectives

At the conclusion of the activity, participants will be able to:

  1. Discuss new and updated treatment options for patients with hematologic malignancies and solid tumors
  2. Identify side effects, indications, and contra-indications of therapies used to diagnose and treat cancers
  3. Explain how to effectively manage side effects associated with cancer treatment
  4. Review abstracts presented at ASCO® 2023 and discuss their application in clinical settings

 

Course summary
Available credit: 
  • 11.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 11.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 11.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 11.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 11.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 11.00 Contact Hours.
Course opens: 
01/31/2023
Course expires: 
11/13/2023
Event starts: 
08/12/2023 - 8:00am PDT
Event ends: 
08/13/2023 - 12:15pm PDT
Cost:
$350.00
Add to calendar: 

Conference Co-Chairs: Dr. Shaji Kumar & Siddhartha Yadav, MD, MBBS

DAY 1 – August 12, 2023

All times are listed in Central Daylight Time (CDT)

07:00 – 08:00 AM: REGISTRATION, BREAKFAST, EXHIBITS

08:00 – 08:05 AM: Welcome - Shaji Kumar, MD

08:05 – 08:15 AM: Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD

08:15 – 09:45 AM: SESSION 1 - HEMATOLOGIC MALIGNANCIES 
Moderator: Shaji Kumar, MD

08:15 – 08:45 AM: Multiple Myeloma - Prashant Kapoor, MD

08:45 – 09:15 AM: Lymphoma & CLL - Parameswaran Venugopal, MD

09:15 – 09:45 AM: Q & A

09:45 – 10:30 AM: BREAK AND EXHIBITS

Industry Sponsored Symposium Sponsored by Exelixis in Waterford Room

Presentation Title: A Combination Treatment for Patients with Advanced Renal Cell Carcinoma

Speaker: John Berry, MD | Loyola MacNeal Cancer Center

This program is not part of the CME activity.

10:30 – 11:30 AM: SESSION 2 - THORACIC ONCOLOGY 
Moderator: Dipesh Uprety, MD, FACP

10:30 – 11:00 AM: Early-Stage Lung Cancer - Julian R. Molina, MD, PhD

11:00 – 11:30 AM: Metastatic Lung Cancer - Robert Kratzke MD

11:30 AM – 12:15 PM: SESSION 3 - CASE-BASED PRESENTATIONS

Moderator: Shaji Kumar, MD

Marissa Li, MD

12:15 – 01:15 PM: LUNCH AND EXHIBITS

12:30 PM to 1:15 PM – Industry Sponsored Symposium Sponsored by Stemline Therapeutics in Waterford Room

Presentation Title: The first and Only Therapy Indicated for ER+/HER2- ESR1 mutated mBC Following at Least One Line of Endocrine Therapy

Speaker: Anne O'Dea, MD / University of Kansas Medical Center (UKMC)

This program is not part of the CME Activity

01:15 – 03:15 PM: SESSION 4 - GENERAL ONCOLOGY 
Moderator: Thanh Ho, MD

01:15 – 01:45 PM: Gynecologic Cancer - Andrea Wahner Hendrickson, MD

01:45 – 02:15 PM: Brain Tumor Updates - Manmeet S. Ahluwalia, MD, MBA

02:15 – 02:45 PM: Head Neck Cancer - Katharine A. Price, MD

02:45 – 03:15 PM: Sarcoma Updates - Brittany Siontis, MD

03:15 – 03:45 PM: BREAK AND EXHIBITS

03:45 – 05:00 PM: SESSION 5 - GENERAL ONCOLOGY
Moderator: Justin Hwang, PhD

03:45 – 04:15 PM: Prostate Cancer - Ulka Vaishampayan, MD

04:15 – 04:45 PM: Early-Stage Breast Cancer - Siddhartha Yadav, MD, MBBS

04:45 – 05:00 PM: Cased-Based Discussion - Sarah Premji, MD

DAY 2 – August 13, 2023

07:00 – 08:00 AM: REGISTRATION, BREAKFAST, EXHIBITS

08:00 – 08:30 AM: SESSION 6 - SKIN CANCER
Moderator: Siddhartha Yadav, MD

08:00 – 08:30 AM: Melanoma Update - Arkadiusz Z. Dudek, MD, PhD

08:30 – 10:00 AM: SESSION 7 - GI CANCER 
Moderator: Ajay Prakash MD, PhD

08:30 – 09:00 AM: Colorectal Cancer - Joleen Hubbard, MD

09:00 – 09:30 AM: Hepatobiliary and Pancreatic Malignancies - Robert McWilliams, MD

09:30 – 10:00 AM: Upper GI Cancer - Anup Kasi, MD, MPH

10:00 – 10:15 AM: BREAK AND EXHIBITS

10:15 – 11:45 AM: SESSION 8 - BREAST CANCER 
Moderator: Yang Liu, MD

10:15 – 10:45 AM: Metastatic Breast Cancer 1 (Hormone Receptor-Positive) - David Potter, MD, PhD

10:45 – 11:15 AM: Metastatic Breast Cancer 2 (HER2+ve and Triple-Negative Breast Cancer) - Roberto Leon-Ferre, MD

11:15- 11:45 AM: Bladder and Kidney Cancer - Nicholas Zorko, MD, PhD

11: 45 AM- 12:45 PM: SESSION 9 - LUNCH & CASE-BASED PRESENTATIONS 

Moderator: Siddhartha Yadav, MD, MBBS

Binav Baral, MBBS; Dhauna Karam, MD; Aparna Basu, MD

Hyatt Regency Bloomington Minneapolis
3200 E 81st St
Bloomington, MN 55425
United States

A limited number of rooms have been booked at the Hyatt Regency Bloomington for participants of this meeting at a discounted room rate of $149/night for the standard rooms. 

RESERVATION

Individual Reservations must be made no later than July 21, 2023. If Guestrooms are available after the cut-off date, they will be offered the Best Available Rate. Check in time is 3:00 p.m. and check out time is 11:00 a.m.

Link to book your hotel room - https://www.hyatt.com/en-US/group-booking/MSPRB/G-MNOC

 Individual Call In – Please contact reservations direct at (800) 233-1234.

Once an individual reservation has been made, any changes should be made directly with our Group Reservations Department. A credit card number or one night’s advance deposit will be required to secure a room out of this block. Cancellations must be received 72 hours before arrival or one night’s room, and tax will be assessed. Upon check-in, a $100 pre-authorized hold will be charged to the credit card.

If reservation is booked on behalf of another person(s), please contact the hotel directly to submit a signed credit card form to authorize payment.

Travel

The hotel will provide complimentary shuttle to/from Mall of America & the Minneapolis Airport to the attendees of this meeting.

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

Course Director(s)

Shaji Kumar, MD

has a financial relationship (Grant Or Contract) with Research funding for clinical trials to the institution: Abbvie, Amgen, BMS, Carsgen,  Janssen,  ,  Astra-Zeneca, Novartis, Roche-Genentech,  Takeda, Tenebio, Molecular Templates;.
has a financial relationship (Professional Services) with Consulting/Advisory Board participation: (with no personal payments) Abbvie, Amgen, BMS, Janssen,  Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secure Biotherapeutics and (with personal payment) Oncopeptides, Beigene, Antengene ;.

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.

Siddhartha Yadav, Siddhartha Yadav, MD, FACP

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

Manmeet Ahluwalia

has a financial relationship (Independent contractor) with Varian Medical Systems;.
has a financial relationship (Independent contractor) with Menarini Ricerche;.
has a financial relationship (Professional Services) with Modifi biosciences;.
has a financial relationship (Stock) with MedInnovate Advisors LLC;.
has a financial relationship (Independent contractor) with Novocure;.
has a financial relationship (Independent contractor) with Xoft;.
has a financial relationship (Independent contractor) with Apollomics;.
has a financial relationship (Independent contractor) with Voyager Therapeutics;.
has a financial relationship (Independent contractor) with Theraguix;.
has a financial relationship (Professional Services) with Pyramid Biosciences;.
has a financial relationship (Stock) with Cytodyn;.
has a financial relationship (Independent contractor) with Bayer;.
has a financial relationship (Independent contractor) with GSK;.
has a financial relationship (Independent contractor) with SDP Oncology;.
has a financial relationship (Independent contractor) with Tocagen;.
has a financial relationship (Independent contractor) with Pyramid Biosciences;.
has a financial relationship (Independent contractor) with Anheart Therapeutics;.
has a financial relationship (Professional Services) with Cairn Therapeutics;.
has a financial relationship (Stock) with Mimivax;.
has a financial relationship (Grant Or Contract) with Seagen;.
has a financial relationship (Independent contractor) with Insightec;.
has a financial relationship (Independent contractor) with Cellularity;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Caris Lifesciences;.
has a financial relationship (Independent contractor) with Cairn Therapeutics;.
has a financial relationship (Independent contractor) with Sumitomo Pharma Oncology;.
has a financial relationship (Professional Services) with Bugworks;.
has a financial relationship (Independent contractor) with Kiyatec;.
has a financial relationship (Independent contractor) with Nuvation;.
has a financial relationship (Independent contractor) with Prelude;.
has a financial relationship (Independent contractor) with Viewray;.

Binav Baral, MBBS

has no relevant financial relationships to disclose at this time.

Aparna Basu

has no relevant financial relationships to disclose at this time.

Arkadiusz Dudek, MD, PhD

has no relevant financial relationships to disclose at this time.

Joleen Hubbard, MD

has a financial relationship (Grant Or Contract) with TriOncology;.
has a financial relationship (Grant Or Contract) with Trovogene;.
has a financial relationship (Other) with Merck;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Grant Or Contract) with Pionyr Immunotherapeutics;.
has a financial relationship (Other) with Incyte;.
has a financial relationship (Grant Or Contract) with Hutchison Medipharma;.
has a financial relationship (Grant Or Contract) with Roche;.
has a financial relationship (Other) with BeiGene;.
has a financial relationship (Grant Or Contract) with Bayer;.
has a financial relationship (Grant Or Contract) with Seattle Genetics;.
has a financial relationship (Grant Or Contract) with G1 Therapeutics;.
has a financial relationship (Other) with Bayer;.
has a financial relationship (Grant Or Contract) with Treos Bio;.

Prashant Kapoor

has a financial relationship (Grant Or Contract) with Loxo Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with AbbVie;.
has a financial relationship (Professional Services) with Pharmacyclics;.
has a financial relationship (Professional Services) with Angitia Bio;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Grant Or Contract) with Bristol Myers Squibb,;.
has a financial relationship (Grant Or Contract) with Sanofi;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Oncopeptides;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Grant Or Contract) with Regeneron;.
has a financial relationship (Grant Or Contract) with Karyopharm;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Professional Services) with Kite;.
has a financial relationship (Professional Services) with GlaxoSmithKline;.
has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Grant Or Contract) with Ichnos;.
has a financial relationship (Grant Or Contract) with GlaxoSmithKline;.
has a financial relationship (Professional Services) with X4 Pharmaceuticals;.

Dhauna Karam, MBBS, MD, FACP

has no relevant financial relationships to disclose at this time.

Anup Kasi, MD MPH

has a financial relationship (Professional Services) with Ipsen;.

Robert Kratzke, Professor of Medicine

has a financial relationship (Professional Services) with Mirati;.

Roberto Leon-Ferre

has a financial relationship (Other) with AstraZeneca;.
has a financial relationship (Other) with Gilead;.

Marissa Li

has no relevant financial relationships to disclose at this time.

Robert McWilliams, MD, MSc

has no relevant financial relationships to disclose at this time.

Julian Molina

has no relevant financial relationships to disclose at this time.

David Potter, MD, PhD

has a financial relationship (Professional Services) with Gilead;.

Sarah Premji, MD

has no relevant financial relationships to disclose at this time.

Katharine Price

has no relevant financial relationships to disclose at this time.

Brittany Siontis, MD

has a financial relationship (Other) with Deciphera;.

Ulka Vaishampayan, MD

has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Exelixis;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with sanofi;.

Parameswaran Venugopal, MD

has no relevant financial relationships to disclose at this time.

Andrea Wahner Hendrickson, M.D

has a financial relationship (Other) with Oxcia;.
has a financial relationship (Other) with TORL biotherapeutics;.
has a financial relationship (Other) with Prolynx;.

Siddhartha Yadav, Siddhartha Yadav, MD, FACP

has no relevant financial relationships to disclose at this time.

Nicholas Zorko, MD, PhD

has a financial relationship (Other) with Caris Life Sciences ;.
has a financial relationship (Other) with Telix;.
Moderator(s)

Thanh Ho

has no relevant financial relationships to disclose at this time.

Justin Hwang, PhD

has no relevant financial relationships to disclose at this time.

Yang Liu, MD

has no relevant financial relationships to disclose at this time.

Ajay Prakash, MD/PhD

has no relevant financial relationships to disclose at this time.

Dipesh Uprety, MD, FACP

has a financial relationship (Professional Services) with Daiichi Sankyo, Astrazeneza, and Sanofi.;.
Planning committee(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.

COMMERCIAL SUPPORT ACKNOWLEDGMENT

This activity is supported with an independent medical education grant from the following companies:

  • Novocure, Inc.
  • Seagen

Available Credit

  • 11.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 11.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 11.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 11.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 11.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 11.00 Contact Hours.

 

Price

Cost:
$350.00
Please login or register to take this course.

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is cancelled six weeks before the conference.
  • No refunds will be issued if registration is cancelled after that date.  

No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post tests as well as course evaluations.